Hypertension and hemostatic/fibrinolytic balance disorders

Clinical and Investigative Medicine

Volumn 32, Issue 6, 2009, Pages

  Tabak, O ^a   Gelisgen, R ^b   Uzun, Hafine ^b   Kalender, B ^c   Balci, H ^d   Curgunlu, A ^d   Simsek, G ^d   Karter, Y ^d  

^a Istanbul Education and Research Hospital ^*  (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c KOCAELI UNIVERSITY   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BLOOD PRESSURE; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HEMOLYSIS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 73249136789     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 summary. Adv Data 2002;328:1-32.
2. Glueck CJ, Glueck HI, Hamer T, et al. Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity. Am J Med Sci 1994;307:317- 24.
3. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Hypertension 2003;42:1206-52.
4. Pickering TG, Coats A, Mallion JM, et al. Blood Pressure Monitoring. Task Force V: White coat hypertension. Blood Press Monit 1999;4:333-41.
5. Bhalla A, D'Cruz S, Lehl SS, Singh R. Renovascular Hypertension - Its Evaluation and Management. JIACM 2003;4:139-46.
6. Duffy MJ. The plasminogen activator system: role in malignancy. Current Pharm Design 2004;10:39-49.
7. van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994;90:362- 8.
8. Gough SC, Rice PJ, McCormack L, Chapman C, Grant PJ. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabet Med 1993;10:638-42.
9. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860-7.
10. Morange PE, Alessi MC, Verdier M, Casanova D, Magalon G, Juhan-Vague I. PAI-1 produced ex vivo human adipose tissue is relevant to PAI-1 blood levels. Arterioscler Thromb Vasc Biol 1999;19:1361-5.
11. Jastrzebska M, Widecka K, Ciechanowicz A, et al. Plasminogen activator Inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia. Pol Arch Med Wewn 2005;113:7-20.
12. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 1992;5:207-9.
13. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001;322:531-6.
14. O'Brien E, Coats A, Owens P, et al. Use and interpretation of Ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 2000;320:1128-34.
15. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000;31:26-32.
16. Gensini GF, Comeglio M, Colella A. Classical risk factors and emerging elements in the risk profile. Eur Heart J 1998;19:53-61.
17. Desouza CA, Stevenson ET, Davy KP, Jones PP, Seals DR. Plazma fibrinogen levels in healthy postmenopausal women: physical activity and hormone replacement status. J Gerontol A Biol Sci 1997;52:294-8.
18. Seljeflot I, Arnesen H, Hofstad AE, Os I. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thromb Haemost 2000;83:944-8.
19. Sechi LA, Novello M, Colussi G, et al. Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage. Am J Hypertens 2008;21: 1347-53.
20. Lip G, Blann A, Jones A, Lip P, Beevers D. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997;80:1566-71.
21. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U. Plazma levels of tissue plasminogen activator / plasminogen activator-I complex and von Willebrand factor are significant risk markers for recurrent myocardial in the Stockholm Heart Epidemiology Program ( SHEEP ) study. J Arterioscler Thromb Vasc Biol 2000;20:2019- 23.
22. Cushman M, Legault C, Barrett-Conner E, et al. Effect of postmenopausal hormones on inflammationsensitive proteins: the postmenopausal Estrogen/ Progestin Intervention (PEP) Study. Circulation 1999;100:717-22.
23. Makris T, Stavroulakis G, Papadopoulos D, et al. White coat hypertension and haemostatic/fibrinolytic balance disorders. Eur Cytokine Netw 2006;17:137-141.
24. Haffner SM, Agostino RD Jr, Saad MF, et al. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am J Cardiol 2000;85:1395-1400.
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
26. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996;94:2057-63.
27. Appel SJ, Harrell JS, Davenport ML. Central Obesity, the Metabolic Syndrome and Plasminogen Activator Inhibitor-1 in Young Adults. J Am Acad Nurse Pract. 2005;17:535-41.
28. Cimminiello C, Vigorelli P, Piliego T, et al. Fibrinolytic Response in subjects with hypertriglyceridemia and low HDL cholesterol. Biomed and Pharmacother 1997;51:164-9.
29. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002;287:356-9.
30. Srikumar N, Brown NJ, Hopkins PN, et al. PAI-1 in human hypertension:Relation to hypertensive groups. Am J Hypertens 2002;15:683-90.
31. Coban E, Ozdogan M. The plasma levels of PAI-1 in subjects with white coat hypertension. Int J Clin Pract 2004;58:541-4.
32. Penesova A, Radikova Z, Cizmarova E. The Role of Norepinephrine and Insulin Resistance in an Early Stage of Hypertension. Ann N Y Acad Sci 2008;1148:490-4.
33. Hoffmeister HM, Heller W, Seipel L. Activation markers of coagulation and fibrinolysis: alterations and predictive value in acute coronary syndromes. Thromb Haemost 1999;82:76-9.
34. Naya M, Tsukamoto T, Inubushi M, et al. Elevated plasma PAI-1 is an independent predictor of coronary microvascular dysfunction in hypertension. Circ J 2007;71:348-53.
35. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002;87:448-52.
36. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans. Hypertension 1998;32:965-71.
37. Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000;85:336-44.
38. Vaughan DE, Lazos S, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the reninangiotensin system and thrombosis. J Clin Invest 1995;95:995- 1001.
39. Sechi LA, Novello M, Colussi G, et al. Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage. Am J Hypertens 2008;21:1347-53.
40. Catena C, Novello M, Lapenna R, et al. New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a). J Hypertens 2005;23:1617-31.
41. Poli KA, Tofler GH, Larson MG, et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation. 2000;101:264-9.
42. Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W. Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 2005;93:1069-76.
43. Makris T, Stavroulakis G, Papadopoulos D, et al. White coat hypertension and haemostatic/fibrinolytic balance disorders. Eur Cytokine Netw 2006;17:137-41.